{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:38:23Z","timestamp":1789648703945,"version":"4.0.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Standard-of-care treatment for locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) is surgery with consolidation chemoradiotherapy (CRT) or definitive CRT. There is a paucity of real-world evidence regarding current treatment patterns and downstream outcomes for LA SCCHN in German clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was a non-interventional, observational, retrospective cohort study of newly diagnosed patients with LA SCCHN using routinely collected claims data from a health insurance claims database in Germany (2016\u20132021). Claim records were used to describe the cohort, including incidence, characteristics, treatment patterns, and survival. As permitted by the data, descriptive analyses were stratified by index treatment (surgical resection or definitive non-surgical treatment), tumor site (oral cavity, oropharynx, hypopharynx, or larynx), and sex. The study was descriptive in nature; as such, no statistical comparisons were made.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The LA SCCHN cohort comprised 1,010 patients (827 male and 183 female patients), of whom 39.8% (402\/1,010) received surgical resection and 60.2% (608\/1,010) received definitive non-surgical treatment as part of index treatment. Patients with surgical resection as part of index treatment were characterized by a younger mean age and lower comorbidity indices. After index treatment, three-quarters (74.8%) of the study population received no subsequent SCCHN treatment. Index treatment was similar for male and female patients. The rate of surgical resection and definitive non-surgical treatment was similar in patients with oral cavity cancer [50.6% (128\/253) and 49.4% (125\/253), respectively]; all other tumor sites were treated more frequently (&amp;gt;60%) with definitive non-surgical treatment. The 5-year probability of survival for the overall population was 48.5% (95% CI: 44.4%\u201353.1%). Survival probabilities varied across tumor sites and by index treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Despite index treatment being broadly aligned to guideline recommendations, most patients did not receive a subsequent line of treatment and almost half of patients had died within 5 years. This highlights the urgent unmet need for improved treatment options for LA SCCHN.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1547311","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:19:46Z","timestamp":1749107986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world treatment patterns and survival outcomes in patients with locally advanced squamous cell carcinoma of the head and neck in Germany using claims data"],"prefix":"10.3389","volume":"15","author":[{"given":"Kathrin","family":"Hering","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kuhnt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Kossack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schultze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Osowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Henkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christin","family":"Gaupel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Solbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Zolyniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Schoenherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30445-X","article-title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","volume":"18","author":"Gatta","year":"2017","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41415-022-5166-x","article-title":"Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors","volume":"233","author":"Gormley","year":"2022","journal-title":"Br Dent J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s44276-024-00089-z","article-title":"Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001\u20132020)","volume":"2","author":"Smith","year":"2024","journal-title":"BJC Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.23","article-title":"Regional outcome disparities in German head and neck cancer patients: Shorter survival in Eastern Germany","volume":"12","author":"Vahl","year":"2023","journal-title":"Cancer Med"},{"key":"B7","unstructured":"Global cancer observatory: Germany\n          \n          \n          \n          2022"},{"key":"B8","article-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae)","volume-title":"Head and neck cancers. Version 1.2025","year":"2024"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.2019190022","article-title":"Critical changes in the staging of head and neck cancer","volume":"2","author":"Glastonbury","year":"2020","journal-title":"Radiol Imaging Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.05.009","article-title":"HPV and oropharyngeal cancer in the Eighth Edition of the TNM Classification: Pitfalls in practice","volume":"12","author":"Hoffmann","year":"2019","journal-title":"Transl Oncol"},{"key":"B11","first-page":"1","volume-title":"Oropharynxkarzinome: Wenn humane Papillomviren die Tumorausl\u00f6ser sind Supplement Onkologie 2","author":"Wittekindt","year":"2018"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.06.2041","article-title":"Real-world treatment patterns of older adults with locally advanced SCCHN using SEER-Medicare","volume":"117","author":"Zhou","year":"2023","journal-title":"Int J Radiat Oncology Biology Physics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and neck cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01522","article-title":"Treating patients with locally advanced squamous cell carcinoma of the head and neck unsuitable to receive cisplatin-based therapy","volume":"9","author":"Porceddu","year":"2019","journal-title":"Front Oncol"},{"key":"B15","unstructured":"S3-Leitlinie diagnostik, therapie und nachsorge des larynxkarzinoms, Langversion 1.1\n          \n          \n          \n          2019"},{"key":"B16","unstructured":"S3-Leitlinie diagnostik und therapie des mundh\u00f6hlenkarzinoms, Langversion 3.0\n          \n          \n          \n          2021"},{"key":"B17","unstructured":"S3-Leitlinie diagnostik, therapie, pr\u00e4vention und nachsorge des oro- und hypopharynxkarzinoms, Langversion 1.0\n          \n          \n          \n          2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/cancers13020338","article-title":"Recent advances and future directions in clinical management of head and neck squamous cell carcinoma","volume":"13","author":"Muzaffar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5607-3_30","article-title":"5-Fluorouracil\/folinic acid\/cisplatin-combination and simultaneous accelerated split-course radiotherapy in advanced head and neck cancer","volume":"244","author":"Hartenstein","year":"1988","journal-title":"Adv Exp Med Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02533-1","article-title":"SEOM clinical guidelines for the treatment of head and neck cancer (2020)","volume":"23","author":"Mesia","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00199","article-title":"Treatment of elderly patients with squamous cell carcinoma of the head and neck","volume":"6","author":"Szturz","year":"2016","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2022.12.015","article-title":"Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial","volume":"183","author":"Tao","year":"2023","journal-title":"Eur J Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.3390\/cancers13102371","article-title":"Recurrent\/metastatic squamous cell carcinoma of the head and neck: a big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies","volume":"13","author":"Ionna","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00072","article-title":"Evidence-based treatment options in recurrent and\/or metastatic squamous cell carcinoma of the head and neck","volume":"7","author":"Argiris","year":"2017","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s40425-019-0662-5","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","volume":"7","author":"Cohen","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B26","unstructured":"What is WIG2\n          \n          \n          \n          2024"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00117-020-00760-9","article-title":"Guideline on diagnosis, treatment, and follow-up of laryngeal cancer","volume":"60","author":"Bootz","year":"2020","journal-title":"Radiologe"},{"key":"B28","volume-title":"ICD-10-GM version 2020. Systematisches verzeichnis","year":"2019"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis","volume":"100","author":"St\u00e4nder","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.3390\/cancers13112635","article-title":"Resection margins in head and neck cancer surgery: an update of residual disease and field cancerization","volume":"13","author":"Pierik","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyae029","article-title":"Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck","volume":"54","author":"Kiyota","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12885-020-07297-z","article-title":"Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13\u201301)","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S855","DOI":"10.1016\/j.annonc.2022.07.806","article-title":"682P Patient characteristics and treatment patterns of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): A retrospective cohort analysis of real-world data in England","volume":"33","author":"Kong","year":"2022","journal-title":"Ann Oncology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1016\/j.jval.2023.03.2086","article-title":"RWD57 Real-world treatment patterns of elderly patients with locally advanced squamous cell carcinoma of the head and neck in the US","volume":"26","author":"Lu","year":"2023","journal-title":"Value Health"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2015.0659","article-title":"Primary surgery vs chemoradiation treatment of advanced-stage hypopharyngeal squamous cell carcinoma","volume":"141","author":"Harris","year":"2015","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"B36","unstructured":"The \u201caccidental\u201d cure\u2014platinum-based treatment for cancer: the discovery of cisplatin\n          \n          \n          \n          2014"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102585","DOI":"10.1016\/j.ctrv.2023.102585","article-title":"Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care","volume":"119","author":"Haddad","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B38","article-title":"Cisplatin","volume-title":"StatPearls","author":"Gold","year":"2024"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e23275","DOI":"10.1200\/JCO.2024.42.16_suppl.e23275","article-title":"Real-world treatment patterns and overall survival (OS) in locoregionally advanced head and neck squamous cell carcinoma (LA HNSCC) in the U.S","volume":"42","author":"Zheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1155893","article-title":"Real-world study of patients with locally advanced HNSCC in the community oncology setting","volume":"13","author":"Black","year":"2023","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/cancers13205206","article-title":"The key differences between human papillomavirus-positive and -negative head and neck cancers: Biological and clinical implications","volume":"13","author":"Powell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1132486","article-title":"Superior loco-regional control after primary surgery compared to chemo-radiotherapy for advanced stage laryngeal cancer","volume":"13","author":"Shelan","year":"2023","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24443","article-title":"Primary surgery for advanced-stage laryngeal cancer: A stage and subsite-specific survival analysis","volume":"38","author":"Harris","year":"2016","journal-title":"Head Neck"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-008-0846-y","article-title":"Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial)","volume":"266","author":"Dietz","year":"2009","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1394691","article-title":"Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol","volume":"14","author":"Wichmann","year":"2024","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v122.18","article-title":"Comparative effectiveness of surgical and nonsurgical therapy for advanced laryngeal cancer","volume":"122","author":"Lin","year":"2016","journal-title":"Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v125.19","article-title":"Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer","volume":"125","author":"Patel","year":"2019","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.v12.18","article-title":"Demographics and access to head and neck cancer care in rural areas compared to urban areas in Germany","volume":"12","author":"Vahl","year":"2023","journal-title":"Cancer Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2016.01.007","article-title":"Status and perspectives of claims data analyses in Germany - a systematic review","volume":"120","author":"Kreis","year":"2016","journal-title":"Health Policy"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-016-0849-3","article-title":"Access, use, and challenges of claims data analyses in Germany","volume":"18","author":"Neubauer","year":"2017","journal-title":"Eur J Health Econ"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1547311\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T07:19:50Z","timestamp":1749107990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1547311\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":50,"alternative-id":["10.3389\/fonc.2025.1547311"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1547311","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"article-number":"1547311"}}